NEWAMSTERDAM PHARMA COMPANY N.V.
NAMSLoading price...
Overview
Previous Close28.46
Open28.37
Ask35.39
Bid20.43
Day's Range27.31 - 28.76
52 Week Range21.23 - 42.21
PE Ratio(TTM)--
Market Cap3.25B
Volume956.63k
Avg. Volume1.29M
12 Months Earnings-212.73M
12 Months Revenue22.57M
Profit/Loss
| PARTICULARS | TTM | 2025 | 2025 | 2024 | 2023 | 2022 | 2022 |
|---|---|---|---|---|---|---|---|
| Operating Revenue | 22.57M | 22.50M | 64.01M | 45.56M | 14.09M | 102.69M | 93.50M |
| Operating Expenses | 237.74M | 248.19M | 236.80M | 221.85M | 197.06M | 106.25M | 59.76M |
| Profit after Tax (Net Income) | -212.73M | -203.82M | -165.72M | -241.60M | -176.94M | -22.63M | 35.40M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Naarden, Netherlands
Website: https://www.newamsterdampharma.com
CEO, President & Executive Director: Dr. Michael Harvey Davidson FACC, Facp., M.D.
Employees: 100
About Company:
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.